Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology Pinecast (https://pinecast.com) en-US@Point of Care @Point of Care atpointofcare@gmail.com no Hematology / Oncology @Point of Care Podcasts https://atpointofcare.com/our-apps/#Hematology https://storage.pinecast.net/podcasts/covers/54dff532-909d-4fc8-852b-66c58aef3572/HematologyOncology.png episodic Copyright 2020 At Point of Care, LLC. All rights reserved. https://pinecast.com/feed/oncology-point-of-care-podcast S27:E3 – Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs https://pinecast.com/guid/ae08b184-ecaf-45c3-aef8-9fab9f25587d Thu, 15 Jan 2026 05:20:00 -0000 00:30:38 https://suitehome.atpointofcare.com/library/2720.03/page/0 In this episode, our expert faculty, medical oncologist Dr. Heather Wakelee, and pathologist Dr. Anil Parwani, explore targeted antibody-drug conjugates (ADCs) in the management of non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs). Discussion will include why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC, quantitative continuous scoring (QCS) as a predictive biomarker, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated adverse events (AEs). 

Visit https://suitehome.atpointofcare.com/library/2720.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Treating NSCLC Without Actionable Mutations: The Role of TROP2 ADCs no 27 3 S27:E2 – TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib https://pinecast.com/guid/94a22bad-9e2d-49dd-b748-79cd70218e39 Thu, 15 Jan 2026 05:10:00 -0000 00:28:36 https://suitehome.atpointofcare.com/library/2720.02/page/0 In this episode, Dr. Charu Aggarwal and Dr. Heather Wakelee explore targeted antibody-drug conjugates (ADCs) in the management of EGFR-mutated NSCLC. Their discussion will include: 1) why trophoblast cell surface antigen 2 (TROP2) is a promising target in NSCLC; 2) quantitative continuous scoring (QCS) as a predictive biomarker; 3) current efficacy and safety data from clinical trials; and 4) best practices for monitoring and mitigating ADC-associated toxicities. 

Visit https://suitehome.atpointofcare.com/library/2720.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> TROP2-Directed ADCs in EGFR-Mutated NSCLC: What Comes After Osimertinib no 27 2 S27:E1 – HER2-Directed ADCs in Advanced NSCLC https://pinecast.com/guid/e5a0a203-de19-4b68-9205-b75c1806e9e4 Thu, 15 Jan 2026 05:00:00 -0000 00:24:44 https://suitehome.atpointofcare.com/library/2720.01/page/0 In this episode, medical oncologist Dr. Charu Aggarwal and nurse practitioner Beth Sandy explore human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates (ADCs) in the management of advanced non-small cell lung cancer. Their engaging discussion will include topics such as HER2 biomarker testing, current efficacy and safety data from clinical trials, and best practices for monitoring and mitigating ADC-associated toxicities. 

Visit https://suitehome.atpointofcare.com/library/2720.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> HER2-Directed ADCs in Advanced NSCLC no 27 1 S26:E3 – Rewriting the ET Playbook https://pinecast.com/guid/796125fe-a01f-479b-8bfc-4d50a9462e5d Fri, 31 Oct 2025 15:00:00 -0000 00:25:02 https://suiteweb.atpointofcare.com/#library/mpn/2718.03/page/0 In this episode, Rewriting the ET Playbook, Dr. Douglas Tremblay and Dr. Ruben Mesa review the current therapeutic options for treating essential thrombocythemia, and they review therapies on the horizon that are currently in late-stage clinical trials. What do clinicians need to know for managing this blood disorder?

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Rewriting the ET Playbook no 26 3 S26:E2 – Treatment Success in PV https://pinecast.com/guid/0228630d-c461-45a6-b239-9e269ca5a635 Fri, 31 Oct 2025 14:00:00 -0000 00:26:13 https://suiteweb.atpointofcare.com/#library/mpn/2718.02/page/0 In this episode, Treatment Success in PV, Dr. Douglas Tremblay and Dr. Ruben Mesa focus on the goals of therapy for polycythemia vera, namely improving symptom burden and reducing thrombosis.

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Treatment Success in PV no 26 2 S26:E1 – From Clues to Classification: PV and ET Diagnosis and Risk Stratification https://pinecast.com/guid/e4483cc8-0b14-4119-ad48-73fbe4b3c6b6 Fri, 31 Oct 2025 13:00:00 -0000 00:29:08 https://suiteweb.atpointofcare.com/#library/mpn/2718.01/page/0 In this episode, From Clues to Classification, PV and ET Diagnosis Risk Stratification, Dr. Douglas Tremblay and Dr. Ruben Mesa discuss how clinicians can make an accurate diagnosis for these two blood disorders and how to prevent vascular complications, particularly how risk stratification can guide therapeutic shared decision-making.

Visit https://suiteweb.atpointofcare.com/#library/mpn/2718.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> From Clues to Classification: PV and ET Diagnosis and Risk Stratification no 26 1 S25:E2 – Managing RET Fusion-Positive NSCLC https://pinecast.com/guid/74ff1466-de1c-436f-8428-2ed9321d9665 Mon, 14 Jul 2025 01:04:53 -0000 00:27:18 https://suitehome.atpointofcare.com/library/2694.02/page/0?subdomain=nsclc In this episode, our faculty, Dr. Justin F. Gainor and Elizabeth A. Krueger, CNP, discuss practical and evidence-based strategies for managing patients with RET fusion-positive NSCLC. Learn about the defining pathologic features that distinguish this lung cancer, the recommended testing modalities for RET fusions, treatment selection, and how to manage adverse effects.

Visit https://suitehome.atpointofcare.com/library/2694.02/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Managing RET Fusion-Positive NSCLC no 25 2 S25:E1 – ALK-Positive NSCLC: Navigating the Treatment Landscape https://pinecast.com/guid/6f09fe12-1494-48a4-8a9a-e8b5acafc108 Mon, 14 Jul 2025 00:54:58 -0000 00:26:49 https://suitehome.atpointofcare.com/library/2694.01/page/0?subdomain=nsclc In this episode, our faculty, Dr. Charu Aggarwal and Beth Sandy, MSN, CRNP, FAPO, discuss biomarker testing, first-line treatment decisions, including some of the latest clinical data from the anaplastic lymphoma kinase (ALK) trials, and real-world strategies to manage toxicities in patients with ALK-positive NSCLC.

Visit https://suitehome.atpointofcare.com/library/2694.01/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> ALK-Positive NSCLC: Navigating the Treatment Landscape no 25 1 S24:E3 – Evidence-Based Strategies for Individualizing CAR T-Cell Therapy in Patients With RRMM https://pinecast.com/guid/23fa360a-407f-481c-95a2-85522469cfda Fri, 27 Jun 2025 18:23:43 -0000 00:22:41 https://suitehome.atpointofcare.com/library/2676.13/page/0?subdomain=myeloma In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss what clinicians need to know about optimizing treatment strategies for their patients with multiple myeloma. They explore approaches to bridging therapy to improve efficacy and reduce toxicity, evidence-based principles for sequencing B-cell maturation antigen (BCMA)-targeted agents, and how to navigate the challenge of prior BCMA exposure to improve patient outcomes.   Visit https://suitehome.atpointofcare.com/library/2676.13/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Evidence-Based Strategies for Individualizing CAR T-Cell Therapy in Patients With RRMM no 24 3 S24:E2 – Identifying Patients for CAR T-Cell Therapy in Earlier Treatment Lines for RRMM https://pinecast.com/guid/b1a720fe-847e-4be6-9977-c5c373549dcf Fri, 27 Jun 2025 18:17:55 -0000 00:23:32 https://suitehome.atpointofcare.com/library/2676.12/page/0?subdomain=myeloma In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss patient selection. Who is the ideal candidate for chimeric antigen receptor (CAR) T-cell therapy? The latest evidence from ASH and Tandem meetings adds crucial data to patient selection strategies.   Visit https://suitehome.atpointofcare.com/library/2676.12/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Identifying Patients for CAR T-Cell Therapy in Earlier Treatment Lines for RRMM no 24 2 S24:E1 – CAR T-Cell Therapy Earlier in Treatment for RRMM https://pinecast.com/guid/94a76a7a-d004-4ce3-b10a-209de01e7e17 Fri, 27 Jun 2025 18:09:28 -0000 00:22:52 https://suitehome.atpointofcare.com/library/2676.11/page/0?subdomain=myeloma In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, explore shifting CAR T-cell therapy into earlier lines of treatment for patients with relapsed/refractory disease, and discuss treatment updates recently presented at ASH 2024 and the 2025 Tandem Meetings.  ** Visit https://suitehome.atpointofcare.com/library/2676.11/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit**

]]> CAR T-Cell Therapy Earlier in Treatment for RRMM no 24 1 S23:E3 – Staying the Course in Metastatic Breast Cancer https://pinecast.com/guid/af527bb0-ecf2-4dec-b840-3e97051b44b6 Sat, 21 Jun 2025 01:07:38 -0000 00:28:54 In this episode, Staying the Course in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Marissa Marti-Smith talk about the importance of shared decision making and patient education. What do your patients need to know about the latest data on toxicities and toxicity management to help them better adhere to their treatment regimen?

Visit https://suitehome.atpointofcare.com/library/2685.03/page/0?subdomain=breastcancer to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Staying the Course in Metastatic Breast Cancer no 23 3 S23:E2 – Mapping the Pathway in Metastatic Breast Cancer https://pinecast.com/guid/c4cfee94-00fd-4e88-a98a-5916cc6b93eb Sat, 21 Jun 2025 01:05:48 -0000 00:29:03 https://suitehome.atpointofcare.com/library/2685.02/page/0?subdomain=breastcancer In this episode, Mapping the Pathway in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Dr. Reshma Mahtani take a deeper dive into the phosphatidylinositol 3-kinase (PI3K) and AKT inhibitors for the treatment of metastatic hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This episode will help you better understand these treatments as well as the causes of treatment resistance.   Visit https://suitehome.atpointofcare.com/library/2685.02/page/0?subdomain=breastcancer to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Mapping the Pathway in Metastatic Breast Cancer no 23 2 S23:E1 – Testing the Waters in Metastatic Breast Cancer https://pinecast.com/guid/7ba6f3e4-1030-46a6-b702-9d315af16b08 Sat, 21 Jun 2025 00:31:36 -0000 00:29:34 https://suitehome.atpointofcare.com/library/2685.01/page/0?subdomain=breastcancer In this episode, Testing the Waters in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Dr. Michelle Shiller discuss biomarkers and the best practices in biomarker testing for patients with metastatic hormone receptor (HR)-positive and human epidermal growth factor 2 (HER2)-negative breast cancer. What do you need to know about this important topic to ensure the very best care for your patients?

Visit https://suitehome.atpointofcare.com/library/2685.01/page/0?subdomain=breastcancer to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Testing the Waters in Metastatic Breast Cancer no 23 1 S22:E3 – Compare Your TROP2-directed ADC in Non-Small Cell Lung Cancer Treatment-Related Adverse Events Management Plan to the Experts https://pinecast.com/guid/001235f5-6a50-4e70-8506-dd37057bcad6 Sat, 31 May 2025 00:59:00 -0000 00:26:04 https://suitehome.atpointofcare.com/library/2674.03/page/0?subdomain=nsclc In this episode, our Faculty, Dr. Charu Aggarwal and Dr. Jacob Sands, explore the clinical impact of investigational TROP2-directed antibody-drug conjugates (ADCs), their safety profile, and expert strategies for managing potential toxicities.

Visit https://suitehome.atpointofcare.com/library/2674.03/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Compare Your TROP2-directed ADC in Non-Small Cell Lung Cancer Treatment-Related Adverse Events Management Plan to the Experts no 22 3 S22:E2 – Advances in TROP2-directed ADCs for Non-Small Cell Lung Cancer: First-Line and Combination Therapies https://pinecast.com/guid/1e17164d-3675-4efd-8552-c4114eb803db Sat, 31 May 2025 00:48:02 -0000 00:25:53 https://suitehome.atpointofcare.com/library/2674.02/page/0?subdomain=nsclc In this episode, our Faculty, Dr. Charu Aggarwal and Dr. Jacob Sands, discuss ongoing clinical trials, evolving biomarker approaches using Quantitative Continuous Scoring (QCS), and the future of personalized care in lung cancer.

Visit https://suitehome.atpointofcare.com/library/2674.02/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Advances in TROP2-directed ADCs for Non-Small Cell Lung Cancer: First-Line and Combination Therapies no 22 2 S22:E1 – TROP2-directed ADCs in the Second Line: Updates from Clinical Trials in NSCLC https://pinecast.com/guid/cf0fb1de-f554-4c83-9efc-bd662c577e87 Sat, 31 May 2025 00:29:27 -0000 00:27:53 https://suitehome.atpointofcare.com/library/2674.01/page/0?subdomain=nsclc In this episode, our Faculty, Dr. Charu Aggarwal and Dr. Jacob Sands, explore the evolving landscape of TROP2-directed antibody-drug conjugates in second-line NSCLC treatment. Hear their expert insights on recent clinical trial updates and what these findings mean for treatment sequencing, biomarker-driven care, and the future of NSCLC management.   Visit https://suitehome.atpointofcare.com/library/2674.01/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> TROP2-directed ADCs in the Second Line: Updates from Clinical Trials in NSCLC no 22 1 S21:E2 – Individualizing Care Plans for Patients With AML https://pinecast.com/guid/962dde28-4744-4a97-b3bc-c071d795061a Mon, 30 Sep 2024 07:01:00 -0000 00:24:25 https://suiteweb.atpointofcare.com/#library/mds-aml/2646.02/page/0 In this episode, Individualizing Care Plans for Patients With AML, Dr. Amer Zeidan and Dr. Guillermo Garcia-Manero discuss how to incorporate evidence-based treatment plans for patients with AML who are receiving oral HMA maintenance therapy. Who are the best candidates for these therapies?

Visit https://suiteweb.atpointofcare.com/#library/mds-aml/2646.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Individualizing Care Plans for Patients With AML no 21 2 S21:E1 – Improving Survival With HMA Maintenance Therapy in AML https://pinecast.com/guid/fb7275ee-940c-40a9-935a-6b17785b2390 Mon, 30 Sep 2024 07:00:00 -0000 00:42:27 https://suiteweb.atpointofcare.com/#library/mds-aml/2646.01/page/0 In this episode, Improving Survival With HMA Therapy in AML, Dr. Amer Zeidan and Dr. Guillermo Garcia-Manero discuss the latest clinical trial evidence for using hypomethylating agents as maintenance therapy for AML patients as well as which patients will benefit most from these therapies.

Visit https://suiteweb.atpointofcare.com/#library/mds-aml/2646.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Improving Survival With HMA Maintenance Therapy in AML no 21 1 S20:E3 – Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies https://pinecast.com/guid/58b76fe4-080b-472d-9293-f4de9c52a45c Mon, 29 Jan 2024 16:00:00 -0000 00:22:43 https://suitehome.atpointofcare.com/library/2606.13/page/0?subdomain=nsclc In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar.   Visit https://suitehome.atpointofcare.com/library/2606.13/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Identifying and Managing Treatment-Related Adverse Events (TRAEs) Associated With TROP2-Targeting Therapies no 20 3 S20:E1 – Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC) https://pinecast.com/guid/781c773f-c188-40e8-b4ef-5138394ada08 Mon, 29 Jan 2024 15:00:00 -0000 00:26:19 https://suiteweb.atpointofcare.com/#library/nsclc/2606.11/page/0 In this episode, Clinical Implications of Trophoblast-Cell Surface Antigen 2 in Non-Small Cell Lung Cancer, Dr. Justin Gainor and Dr. Helena Yu discusses the current diagnosis and treatment of non-small cell lung cancer as well as a new ADC target, trophoblast cell-surface antigen 2 or Trop2.

Visit https://suiteweb.atpointofcare.com/#library/nsclc/2606.11/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Clinical Implications of Trophoblast-Cell Surface Antigen 2 (TROP2) in Non-Small Cell Lung Cancer (NSCLC) no 20 1 S20:E2 – Latest Clinical Trial Data of Emerging, TROP2-Targeting Agents in Advanced NSCLC https://pinecast.com/guid/6021a387-5ca0-4964-8715-1516963a4424 Mon, 29 Jan 2024 15:00:00 -0000 00:30:30 https://suitehome.atpointofcare.com/library/2606.12/page/0?subdomain=nsclc In this episode our faculty look at some of the clinical data on anti-Trop-2 treatments and why they may be heralding an exciting future for the treatment of non-small cell lung cancer.   Visit https://suitehome.atpointofcare.com/library/2606.12/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

]]> Latest Clinical Trial Data of Emerging, TROP2-Targeting Agents in Advanced NSCLC no 20 2 S19:E3 – Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer https://pinecast.com/guid/3e1d6769-e181-4b9e-bde3-509f4ebd1d03 Fri, 29 Dec 2023 18:00:02 -0000 00:26:12 http://www.morningcommutepodcast.com/HER3Agnostic3 Our faculty continue their discussion about clinical trials of HER3-directed therapies with a look at treatment-related adverse events and how to manage them.

Visit www.morningcommutepodcast.com/HER3Agnostic3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: What Clinicians Should Know about Treatment-Related Adverse Events from HER3-Directed ADCs in Breast and Lung Cancer no 19 3 S19:E2 – Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer https://pinecast.com/guid/5a9e858b-83d6-4019-86b0-c68103759991 Fri, 29 Dec 2023 17:58:01 -0000 00:30:48 http://www.morningcommutepodcast.com/HER3Agnostic2 In this episode our faculty take a look at the clinical trial data on HER3-directed therapies for breast and lung cancer.

Visit www.morningcommutepodcast.com/HER3Agnostic2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: A Review of Trial Data on HER3 in Non-Small Cell Lung Cancer and Breast Cancer no 19 2 S19:E1 – Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer? https://pinecast.com/guid/826334a7-5af0-4dba-95bc-8b5a232614ab Fri, 29 Dec 2023 17:56:19 -0000 00:25:35 http://www.morningcommutepodcast.com/HER3Agnostic1 In this episode, our faculty discuss the widespread expression of human epidermal growth factor receptor 3 (HER3) across tumor types and why clinicians should have HER3 on their radar.

Visit www.morningcommutepodcast.com/HER3Agnostic1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: Should HER3 Be Considered a Tumor-Agnostic Target in Breast and Lung Cancer? no 19 1 S18:E3 – Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits https://pinecast.com/guid/c64dc563-2e31-49a1-8415-b69b18abca41 Thu, 30 Nov 2023 17:02:39 -0000 00:28:03 http://www.morningcommutepodcast.com/HRPositiveBreast3 In this episode our faculty take a look at the ins and outs of molecular testing in patients with HR+ positive breast cancer.

Visit www.morningcommutepodcast.com/HRPositiveBreast3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: Biomarker Testing in HR+ Breast Cancer—If the Shoe Fits no 18 3 S18:E2 – Morning Commute Podcast: Embracing HER2-Low, Trop2-Directed, and Other Newer Approaches to HR-Positive Breast Cancer https://pinecast.com/guid/62ef62a9-e832-4d84-97d1-123db5e3c58f Thu, 30 Nov 2023 16:59:36 -0000 00:30:02 http://www.morningcommutepodcast.com/HRPositiveBreast2 In this podcast, our faculty take a look at some of the clinical data behind the newer treatment strategies for HR-positive breast cancer as well as how to address and manage some associated adverse events.

Visit www.morningcommutepodcast.com/HRPositiveBreast2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: Embracing HER2-Low, Trop2-Directed, and Other Newer Approaches to HR-Positive Breast Cancer no 18 2 S18:E1 – Morning Commute Podcast: An AKTor and Supporting Cast Take the Stage in HR+ Breast Cancer https://pinecast.com/guid/eae45a3a-79a8-4fa4-9939-a2cd1b697645 Thu, 30 Nov 2023 16:58:10 -0000 00:23:49 http://www.morningcommutepodcast.com/HRPositiveBreast1 In this podcast, our faculty discuss some newer treatment approaches for patients with HR-positive breast cancer including PI3K inhibition, AKT inhibition, and oral selective estrogen receptor down regulators.

Visit www.morningcommutepodcast.com/HRPositiveBreast1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: An AKTor and Supporting Cast Take the Stage in HR+ Breast Cancer no 18 1 S17:E4 – Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia https://pinecast.com/guid/f3c85d45-597a-4cea-9e4e-21c0ac7c26be Wed, 15 Nov 2023 17:25:51 -0000 00:34:09 http://www.morningcommutepodcast.com/aml4 FLT3-inhibitors, such as quizartinib, are changing the treatment paradigm for AML, in this podcast, our faculty take a look at the drug class, how they are used in AML, and how to manage any treatment-related adverse events.

Visit www.morningcommutepodcast.com/aml4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: FLT3 Treatment-Related Adverse Events in Patients with Acute Myeloid Leukemia no 17 4 S17:E3 – Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib https://pinecast.com/guid/66977e13-4faf-4341-ba55-1a3cc8f9445f Wed, 15 Nov 2023 17:24:06 -0000 00:31:48 http://www.morningcommutepodcast.com/aml3 The treatment paradigm for the treatment of AML is changing. In this podcast, our faculty discuss quizartinib and the QuANTUM-First trial. 

Visit www.morningcommutepodcast.com/aml3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: The Rationale for More Potent FLT3 Inhibitors for Acute Myeloid Leukemia – Enter Quizatinib no 17 3 S17:E2 – Morning Commute Podcast: Treatment Options for Newly Diagnosed AML Patients https://pinecast.com/guid/439909e8-0b6a-4a85-97dd-6d51435f9eb8 Wed, 15 Nov 2023 17:22:27 -0000 00:33:39 http://www.morningcommutepodcast.com/aml2 In this podcast our faculty discuss the latest treatment options for AML that target FLT3 mutations: midostaurin, gilteritinib, and the new kid on the block, quizartinib.

Visit www.morningcommutepodcast.com/aml2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: Treatment Options for Newly Diagnosed AML Patients no 17 2 S17:E1 – Morning Commute Podcast: The Molecular Landscape of FLT3 Mutations in AML https://pinecast.com/guid/d55c06e5-e46a-48aa-9b92-4afe50e21348 Wed, 15 Nov 2023 17:12:45 -0000 00:26:25 http://www.morningcommutepodcast.com/aml1 Our faculty discuss the importance of biomarker testing for FLT3 and FLT3-ITD and the prognostic impact for these patients, especially now that there are therapies targeting these mutations.

Visit www.morningcommutepodcast.com/aml1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Morning Commute Podcast: The Molecular Landscape of FLT3 Mutations in AML no 17 1 S16:E3 – Oncology Morning Commute: Sequencing Therapies in Endometrial Cancer Beyond the First-line Setting https://pinecast.com/guid/25923f35-43e8-4034-b0ba-43096d62fb3f Wed, 26 Jul 2023 01:10:13 -0000 00:23:15 https://suiteweb.atpointofcare.com/library/endometrial-cancer/2552.03/page/0 In this podcast of our three-part series, our faculty continue their discussion on the treatment of endometrial cancer, this time looking at some of the key data on combination therapies as well as associated adverse events and how to handle them.

Visit www.MorningCommutePodcast.com/Endometrial5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Morning Commute: Sequencing Therapies in Endometrial Cancer Beyond the First-line Setting no 16 3 S16:E2 – Oncology Morning Commute: Is Immunotherapy Replacing Chemo in the First-Line Treatment Setting for Endometrial Cancer? https://pinecast.com/guid/ad8c343e-8786-478a-95ef-e90f5fa14e71 Sat, 31 Dec 2022 02:05:00 -0000 00:26:14 https://suiteweb.atpointofcare.com/library/endometrial-cancer/2552.02/page/0 In this episode of our three-part series on endometrial cancer, our faculty continue their discussion by turning to some of the ongoing, and some may say groundbreaking, clinical trials for the use of immunotherapies in the first-line setting.

Visit www.MorningCommutePodcast.com/Endometrial4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Morning Commute: Is Immunotherapy Replacing Chemo in the First-Line Treatment Setting for Endometrial Cancer? no 16 2 S16:E1 – Oncology Morning Commute: Understanding the Heterogeneity of Endometrial Cancer https://pinecast.com/guid/53b9129a-6e1a-4847-8772-e0053b242d30 Sat, 31 Dec 2022 02:00:00 -0000 00:25:16 https://suiteweb.atpointofcare.com/library/endometrial-cancer/2552.01/page/0 In this podcast, our faculty discuss the heterogeneity of endometrial cancer and its four molecular classifications. How do these classifications help determine patient treatment plans?

Visit www.MorningCommutePodcast.com/Endometrial3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Morning Commute: Understanding the Heterogeneity of Endometrial Cancer no 16 1 S15:E3 – Oncology Morning Commute: HER2+ CRC Therapies in Clinical Practice https://pinecast.com/guid/1ef9e002-72e6-473c-be77-667e1f537dbd Fri, 23 Dec 2022 08:03:00 -0000 00:26:31 http://www.MorningCommutePodcast.com/CRC3 In this final podcast of our 3-part series, our faculty take their discussion of metastatic colorectal cancer and HER2-targeted therapies to the clinical level and share some patient cases. You don't want to miss these clinical pearls.  

Visit http://www.MorningCommutePodcast.com/CRC3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: HER2+ CRC Therapies in Clinical Practice no 15 3 S15:E2 – Oncology Morning Commute: Emerging Data on HER2-Positive Colorectal Cancer Therapies https://pinecast.com/guid/8b918251-d157-46af-8533-d27e274d1e87 Fri, 23 Dec 2022 08:02:00 -0000 00:25:39 http://www.MorningCommutePodcast.com/CRC2 In this podcast, our faculty discuss HER2-positive colorectal cancer. HER2 has long been associated as a biomarker and treatment target for breast cancer, but now it is also a target in some colorectal cancers. Dr. John Marshall and Dr. Sunni Kim take a look at some of the recent clinical data on the investigational therapies targeting HER2-positive colorectal cancer.

Visit http://www.MorningCommutePodcast.com/CRC2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Emerging Data on HER2-Positive Colorectal Cancer Therapies no 15 2 S15:E1 – Oncology Morning Commute: Recognition of Actionable Biomarkers in Colorectal Cancer https://pinecast.com/guid/a7b5ccee-f595-4eec-80d7-a4c007e0db14 Fri, 23 Dec 2022 08:01:00 -0000 00:24:37 http://www.MorningCommutePodcast.com/CRC1 In this first podcast of our three-part series, our faculty discuss biomarkers for colorectal cancer including HER2. Are you aware of the current guideline recommendations for biomarker testing in colorectal cancer?  

Visit http://www.MorningCommutePodcast.com/CRC1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Recognition of Actionable Biomarkers in Colorectal Cancer no 15 1 S14:E3 – Oncology Morning Commute: How Can Physicians Use Best Clinical Judgment to Determine Core Drivers for Cancer Screening? https://pinecast.com/guid/bf5ba447-505b-4cb4-b6c0-6507f89aca80 Thu, 22 Dec 2022 11:03:00 -0000 00:22:48 http://www.MorningCommutePodcast.com/CancerEarlyDetect3 In this final podcast of our 3-part series, our faculty continue their discussion on multicancer early detection tests, this time turning to how to incorporate these tests into clinical practice.  

Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: How Can Physicians Use Best Clinical Judgment to Determine Core Drivers for Cancer Screening? no 14 3 S14:E2 – Oncology Morning Commute: A Review of the Science Behind Multicancer Early Detection Tests https://pinecast.com/guid/03328528-fd8c-4907-9fce-f2bcd6bde499 Thu, 22 Dec 2022 08:02:00 -0000 00:24:27 In the second episode of our podcast series on early cancer detection, our faculty take a closer look at multicancer early detection tests and the groundbreaking PATHFINDER study that so far is showing impressive data.

Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: A Review of the Science Behind Multicancer Early Detection Tests no 14 2 S14:E1 – Oncology Morning Commute: New Approaches to Testing Patients for Cancer https://pinecast.com/guid/c5ba9cc4-93f9-4a74-a9b7-1ce0e3f99462 Thu, 22 Dec 2022 08:01:00 -0000 http://www.MorningCommutePodcast.com/CancerEarlyDetect1 In this podcast, our faculty discuss new methods of detecting cancer, including liquid biopsy and blood based, multicancer early detection tests. Can one blood sample provide accurate screening for many cancers?

Visit http://www.MorningCommutePodcast.com/CancerEarlyDetect1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: New Approaches to Testing Patients for Cancer no 14 1 S13:E3 – Oncology Morning Commute: What’s Next in Using PARP Inhibitors for Patients With Ovarian Cancer? https://pinecast.com/guid/f9f85a8e-091f-451f-bc5a-f94f336798fb Fri, 16 Dec 2022 04:15:02 -0000 00:29:22 http://www.MorningCommutePodcast.com/OvarianCancer3 In this final podcast of our three-part series, our faculty look at some of the latest findings on PARP inhibitors as well as what is on the horizon. They also tackle the topic of disparities in care for patients with ovarian cancer and how clinical trials can address this.

Visit http://www.MorningCommutePodcast.com/OvarianCancer3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: What’s Next in Using PARP Inhibitors for Patients With Ovarian Cancer? no 13 3 S13:E2 – Oncology Morning Commute: Managing Adverse Events That Occur With PARP Inhibition Therapies—What Your Patients Need to Know https://pinecast.com/guid/5e6a2cdb-af56-413c-a40e-7cafcd741a26 Fri, 16 Dec 2022 04:11:57 -0000 http://www.MorningCommutePodcast.com/OvarianCancer2 In this podcast, our faculty continue their discussion about PARP inhibitors and take it down to the clinical level. Who are the best candidates for these therapies and how are adverse events managed for the best outcomes?

Visit http://www.MorningCommutePodcast.com/OvarianCancer2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Managing Adverse Events That Occur With PARP Inhibition Therapies—What Your Patients Need to Know no 13 2 S13:E1 – Oncology Morning Commute: Patient Selection for Treatment With PARP Inhibitors in Ovarian Cancer https://pinecast.com/guid/2a25827b-a5d3-47bd-a06d-4a892109f19c Fri, 16 Dec 2022 04:08:57 -0000 00:29:36 http://www.MorningCommutePodcast.com/OvarianCancer1 What is the history behind the development of PARP inhibitors for the treatment of ovarian cancer and how have they influenced recent guideline changes regarding their use? Our faculty discuss this and more in the first podcast of the three-part series on PARP inhibitors and ovarian cancer.  

Visit http://www.MorningCommutePodcast.com/OvarianCancer1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Patient Selection for Treatment With PARP Inhibitors in Ovarian Cancer no 13 1 S12:E3 – Oncology Morning Commute: Shifting Treatment Sequences in the Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape https://pinecast.com/guid/590ac528-430f-48f9-ba4f-124b92997434 Wed, 23 Nov 2022 02:49:42 -0000 00:22:37 http://www.MorningCommutePodcast.com/BCell3 In the final episode of our series, our faculty discuss the changing treatment landscape for diffuse large B-cell lymphoma. With more and more options, the paradigm is shifting and that's good news.

Visit http://www.MorningCommutePodcast.com/BCell3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Shifting Treatment Sequences in the Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape no 12 3 S12:E2 – Oncology Morning Commute: Antibody-Drug Conjugates and the Changing Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape https://pinecast.com/guid/0277cddf-7a10-4908-834a-22534cee5401 Wed, 23 Nov 2022 02:47:19 -0000 00:22:01 http://www.MorningCommutePodcast.com/BCell2 What are the antibody-drug conjugate treatment options for patients with relapsed or refractory diffuse large B-cell lymphoma? In this podcast our faculty look at key trial data as well as treatment management for this disease.

Visit http://www.MorningCommutePodcast.com/BCell2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Antibody-Drug Conjugates and the Changing Relapsed or Refractory Diffuse Large B-Cell Lymphoma Landscape no 12 2 S12:E1 – Oncology Morning Commute: A Primer on B-Cell Targets in Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://pinecast.com/guid/07535bf8-c292-4769-8abc-8a2feb919ee3 Wed, 23 Nov 2022 02:43:18 -0000 00:21:36 http://www.MorningCommutePodcast.com/BCell1 In this podcast, our faculty discuss relapsed/refractory diffuse large B-cell lymphoma, how refractory disease is defined, and the role of the new antibody-based therapies in relapsed/refractory disease.

Visit http://www.MorningCommutePodcast.com/BCell1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: A Primer on B-Cell Targets in Relapsed or Refractory Diffuse Large B-Cell Lymphoma no 12 1 S11:E6 – Oncology Morning Commute: Have I Got a Follicular Lymphoma Trial for You https://pinecast.com/guid/608c28b6-59b1-430b-afb1-699d55b49610 Sat, 01 Oct 2022 01:37:28 -0000 00:23:44 http://www.MorningCommutePodcast.com/FL6 In this final episode, our faculty discuss clinical trials that are in progress, the importance of the clinical trial process, and how they benefit patients and help move the needle on new and promising treatments.

Visit http://www.MorningCommutePodcast.com/FL6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Have I Got a Follicular Lymphoma Trial for You no 11 6 S11:E5 – Oncology Morning Commute: Safety First in Follicular Lymphoma https://pinecast.com/guid/b8376889-e5f2-4707-bf15-a9ece6c82d48 Sat, 01 Oct 2022 01:35:15 -0000 00:24:56 http://www.MorningCommutePodcast.com/FL5 In this podcast, our faculty discuss the major classes of treatment for follicular lymphoma, including outcomes and managing the expected toxicities.

Visit http://www.MorningCommutePodcast.com/FL5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Safety First in Follicular Lymphoma no 11 5 S11:E4 – Oncology Morning Commute: Making the Case for Follicular Lymphoma Therapy https://pinecast.com/guid/481957ca-721f-4415-b43b-62a50490e68c Sat, 01 Oct 2022 01:26:48 -0000 http://www.MorningCommutePodcast.com/FL4 How is the best way to select and sequence follicular lymphoma therapies? In this episode, our faculty discuss this and more.

Visit http://www.MorningCommutePodcast.com/FL4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Making the Case for Follicular Lymphoma Therapy no 11 4 S11:E3 – Oncology Morning Commute: Follicular Lymphoma—Haven't We Met Before? https://pinecast.com/guid/56280d17-1103-4696-ac97-7c9a35f83a83 Sat, 01 Oct 2022 01:25:14 -0000 00:25:18 http://www.MorningCommutePodcast.com/FL3 In our third podcast in this series, our faculty take a look at third-line treatment options for follicular lymphoma patients.

Visit http://www.MorningCommutePodcast.com/FL3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Follicular Lymphoma—Haven't We Met Before? no 11 3 S11:E2 – Oncology Morning Commute: What Can We Do About Early Relapsing Follicular Lymphoma? https://pinecast.com/guid/a65e8f17-59e7-4213-9cdb-30481e876ffc Sat, 01 Oct 2022 01:20:01 -0000 00:26:56 http://www.MorningCommutePodcast.com/FL2 In this second podcast of our series, our faculty continue their discussion of follicular lymphoma and its treatment, particularly for those patients who progress within the first 24 months, the progression of disease within 2 years (POD24). What is known about predictors of progression and what is the best path forward for these poor prognosis patients?

Visit http://www.MorningCommutePodcast.com/FL2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: What Can We Do About Early Relapsing Follicular Lymphoma? no 11 2 S11:E1 – Oncology Morning Commute: Follicular Lymphoma: A New Patient Walks Into The Clinic https://pinecast.com/guid/38fccc75-0590-45d3-a094-40cfb60df6b9 Sat, 01 Oct 2022 00:35:48 -0000 00:26:09 http://www.MorningCommutePodcast.com/FL1 What are the initial treatment strategies for the newly diagnosed patient with follicular lymphoma? Our faculty discuss this and more in this first episode of our series on follicular lymphoma.   Visit www.MorningCommutePodcast.com/FL1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Follicular Lymphoma: A New Patient Walks Into The Clinic no 11 1 S9:E2 – Oncology Journal Club: How Covid Treatment Advances are Helping CLL Patients https://pinecast.com/guid/a8057195-f2e3-424e-904e-b07fe524b819 Mon, 25 Jul 2022 16:36:00 -0000 http://www.journalclubpodcasts.com/CLLCovid2 There is some good news for preventing and treating Covid in patients with chronic lymphocytic leukemia (CLL). New treatment advances allow clinicians to have a more balanced focus on CLL standards of care with Bruton’s tyrosine kinase (BTK) inhibitors such as ibrutinib and anti-CD20 treatments such as rituximab, and not as much worry about Covid.

Visit journalclubpodcasts.com/CLLCovid2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Journal Club: How Covid Treatment Advances are Helping CLL Patients no 9 2 S10:E5 – Oncology Morning Commute: Toxicity Risks and the New-Generation Treatments for CML https://pinecast.com/guid/13ce0222-8650-41fd-a2a6-b07e5d376a6a Sun, 15 May 2022 21:00:00 -0000 00:14:11 http://www.morningcommutepodcast.com/CML5 As with any treatment, toxicities can be a concern. Our faculty return to discuss toxicities with third-generation tyrosine kinase inhibitors. How can these toxicities be mitigated? How can you maximize benefit and minimize risks?

Visit http://www.morningcommutepodcast.com/CML5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Morning Commute: Toxicity Risks and the New-Generation Treatments for CML no 10 5 S10:E4 – Oncology Morning Commute: Keeping Watch—Treatment Response in CML https://pinecast.com/guid/444eee7f-b79e-4c28-a73b-ff744ec036b6 Sun, 15 May 2022 20:00:00 -0000 00:15:23 http://www.morningcommutepodcast.com/CML4 What are the treatment response benchmarks when treating chronic myeloid leukemia and when, if ever, should therapies be switched? Moreover, how do you know if they are working? Our faculty discuss these questions and more.

Visit http://www.morningcommutepodcast.com/CML4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Keeping Watch—Treatment Response in CML no 10 4 S10:E3 – Oncology Morning Commute: Dialing Down—Optimizing Third-Generation Treatments for CML https://pinecast.com/guid/07ce1bf5-f716-4446-ae31-02d5632bbdc6 Sun, 15 May 2022 19:00:00 -0000 00:14:59 http://www.morningcommutepodcast.com/CML3 When treating patients with chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors, what is the optimal dose? Our faculty discuss this as well as treatment duration and other considerations for using these third-generation therapies.

Visit http://www.morningcommutepodcast.com/CML3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Dialing Down—Optimizing Third-Generation Treatments for CML no 10 3 S10:E2 – Oncology Morning Commute: Targeting STAMP in CML https://pinecast.com/guid/871a765b-fb95-4f0c-9b61-02bf74afd6ee Sun, 15 May 2022 18:00:00 -0000 00:14:54 http://www.morningcommutepodcast.com/CML2 In this podcast our faculty return for a discussion of a new target for the treatment of chronic myeloid leukemia and the newest treatment on the block, asciminib.

Visit http://www.morningcommutepodcast.com/CML2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Targeting STAMP in CML no 10 2 S10:E1 – Oncology Morning Commute: Third-Line Treatment of CML https://pinecast.com/guid/086a16e9-def1-419f-9f57-a74c621a9af5 Sun, 15 May 2022 17:00:00 -0000 00:17:11 http://www.morningcommutepodcast.com/CML1 Third-line treatment of chronic myeloid leukemia and in particular BCR-ABL1 tyrosine kinase inhibitors are the latest therapeutics in the clinician’s toolbox. In this podcast, our faculty discuss these treatments and which patients can derive the most benefit from them.

Visit http://www.morningcommutepodcast.com/CML1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Third-Line Treatment of CML no 10 1 S9:E1 – Oncology Journal Club: Covid-19 and CLL Implications for Treatment Decision-Making https://pinecast.com/guid/affbd268-d3a4-4f9f-a9f2-722486abc008 Sun, 15 May 2022 16:00:00 -0000 http://www.journalclubpodcasts.com/CLLCovid1 How is the Covid-19 pandemic affecting patients with chronic lymphocytic leukemia (CLL)? Our faculty discuss several papers during this podcast that address the efficacy of CLL treatments, especially Bruton’s tyrosine kinase inhibitors, on CLL as well as vaccine response in the treatment decisions for this patient population.

Visit http://www.journalclubpodcasts.com/CLLCovid1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Journal Club: Covid-19 and CLL Implications for Treatment Decision-Making no 9 1 S8:E3 – Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time? https://pinecast.com/guid/9221063e-025c-4eef-bff6-83d7026490e0 Mon, 28 Mar 2022 16:30:00 -0000 00:18:28 http://morningcommutepodcast.com/nsclc6 Our faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates as treatment for this disease. But are they ready for prime time?

Visit http://morningcommutepodcast.com/nsclc6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time? no 8 3 S8:E2 – Oncology Morning Commute: PD-L1 Expression in NSCLC https://pinecast.com/guid/12a68b89-4f70-40b0-9d93-bc662b9f92a1 Mon, 28 Mar 2022 16:20:00 -0000 00:17:56 http://morningcommutepodcast.com/nsclc5 Our faculty takes a look at PD-L1 expression and immunotherapies. Who are the best candidates for these therapies? Who should not receive them?

Visit http://morningcommutepodcast.com/nsclc5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: PD-L1 Expression in NSCLC no 8 2 S8:E1 – Oncology Morning Commute: Molecular Profiling in Non-Small Cell Lung Cancer https://pinecast.com/guid/0c690603-d5bc-4001-9983-da4114a4ba80 Sat, 26 Mar 2022 16:00:00 -0000 00:17:46 http://morningcommutepodcast.com/nsclc4 Our faculty discuss molecular testing for non-small cell lung cancer (NSCLC). Should all patients with NSCLC be tested for biomarkers?

Visit http://morningcommutepodcast.com/nsclc4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Molecular Profiling in Non-Small Cell Lung Cancer no 8 1 S7:E5 – Oncology Morning Commute: Clinical Trials—Ensuring Inclusivity https://pinecast.com/guid/15309b98-19f1-4e91-9b47-9ca7749c9aa0 Tue, 15 Mar 2022 17:50:00 -0000 00:14:29 http://www.morningcommutepodcast.com/disparities5 In this episode our faculty discuss clinical trials in oncology. Are they reflective of the general population of patients who will ultimately be affected by the trial outcomes? What are the factors that impact clinical trial demographics? 

Visit www.morningcommutepodcast.com/disparities5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Clinical Trials—Ensuring Inclusivity no 7 5 S7:E4 – Oncology Morning Commute: Disparities in Care https://pinecast.com/guid/fc21d1cd-93cd-450e-8033-844912b8f7d7 Tue, 15 Mar 2022 17:40:00 -0000 00:13:13 http://www.morningcommutepodcast.com/disparities4 In this episode, our faculty continues their discussion about disparities in oncology care. Is there a solution? How can being team-focused help patients in their cancer care journey?

Visit www.morningcommutepodcast.com/disparities4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Morning Commute: Disparities in Care no 7 4 S7:E3 – Oncology Morning Commute: Addressing Bias in Patient Care https://pinecast.com/guid/78a5900b-4a20-45a9-91e4-e0b05bdd63df Tue, 15 Mar 2022 17:30:00 -0000 00:10:36 http://www.morningcommutepodcast.com/disparities3 How does implicit bias impact patient care? What is unconscious bias and how can clinicians become more aware of their own biases is regard to patient care? Our faculty tackles these topics in this episode.

Visit www.morningcommutepodcast.com/disparities3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Morning Commute: Addressing Bias in Patient Care no 7 3 S7:E2 – Oncology Morning Commute: Improving Equity in Healthcare https://pinecast.com/guid/a2ef170e-6fa7-4766-97dc-568568a00f86 Tue, 15 Mar 2022 17:10:00 -0000 00:12:33 http://www.morningcommutepodcast.com/disparities2 In this episode our faculty will focus on health equity. What causes health inequity? Is it lack of access to care, cancer screenings, early diagnoses? How does socioeconomic variables factor in? These questions and more will be discussed in this podcast.

Visit www.morningcommutepodcast.com/disparities2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Morning Commute: Improving Equity in Healthcare no 7 2 S7:E1 – Oncology Morning Commute: The Health Disparities Landscape https://pinecast.com/guid/16428351-a235-4344-99fb-a57d2414a031 Tue, 15 Mar 2022 17:05:53 -0000 00:14:32 http://www.morningcommutepodcast.com/disparities1 In this episode, our faculty discuss disparities in oncology care. What exactly are health disparities? What populations are most at risk for experiencing disparities in care?

Visit www.morningcommutepodcast.com/disparities1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: The Health Disparities Landscape no 7 1 S6:E6 – Oncology Morning Commute: The Emerging Role for Antibody-Drug Conjugates in GI Cancers https://pinecast.com/guid/3c2409e1-cebb-443f-860a-96960d100d96 Mon, 28 Feb 2022 23:00:00 -0000 00:22:34 http://www.morningcommutepodcast.com/solidtumors6 In this podcast our faculty discuss gastrointestinal (GI) cancers and antibody-drug conjugates. How are these new therapies changing the landscape of GI cancer care? 

Visit www.morningcommutepodcast.com/solidtumors6 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: The Emerging Role for Antibody-Drug Conjugates in GI Cancers no 6 6 S6:E5 – Oncology Morning Commute: Targeted Therapies for Gastroesophageal and Colorectal Cancers https://pinecast.com/guid/ab79786a-2433-492d-8c89-9777696c9345 Mon, 28 Feb 2022 22:00:00 -0000 00:22:11 http://www.morningcommutepodcast.com/solidtumors5 HER2 expression in gastric/gastroesophageal junction and colorectal cancer potentially paves the way for the use of targeted therapies for these cancers. Our faculty discuss these important clinical developments.

Visit www.morningcommutepodcast.com/solidtumors5 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Targeted Therapies for Gastroesophageal and Colorectal Cancers no 6 5 S6:E4 – Oncology Morning Commute: Targeting HER2, HER3, and TROP2 in NSCLC https://pinecast.com/guid/b3a7a432-cd67-4b24-98e6-03098807a28a Mon, 28 Feb 2022 21:00:00 -0000 00:26:53 http://www.morningcommutepodcast.com/solidtumors4 Our faculty continue their discussion on antibody-drug conjugates and look at some of the promising trials in NSCLC for these promising therapies.

Visit www.morningcommutepodcast.com/solidtumors4 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit.

]]> Oncology Morning Commute: Targeting HER2, HER3, and TROP2 in NSCLC no 6 4 S6:E3 – Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time? https://pinecast.com/guid/1020026b-e0e4-41cc-9eb6-ae2390e5c6a5 Mon, 28 Feb 2022 20:00:00 -0000 http://www.morningcommutepodcast.com/solidtumors3 Our faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates as treatment for this disease. But are they ready for prime time?

Visit www.morningcommutepodcast.com/solidtumors3 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time? no 6 3 S6:E2 – Oncology Morning Commute: From HER2 Low to TROP2—Evolving Targeted Therapies for Breast Cancer https://pinecast.com/guid/c5a6e09d-af8a-47d2-9b8a-29fb53c4c648 Mon, 28 Feb 2022 19:00:00 -0000 00:32:01 http://www.morningcommutepodcast.com/solidtumors2 Our faculty continue their discussion of antibody-drug conjugates. They look beyond targeting HER2 and review data on the treatment of metastatic triple-negative breast cancer, HER2 Low expressing breast cancer, and the emerging data on TROP2 and HER3 as new targets for therapy.

Visit www.morningcommutepodcast.com/solidtumors2 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: From HER2 Low to TROP2—Evolving Targeted Therapies for Breast Cancer no 6 2 S6:E1 – Oncology Morning Commute: Antibody Drug Conjugates and HER2-Positive Breast Cancer https://pinecast.com/guid/d6539d6c-9b06-4250-ad97-89665dd82389 Mon, 28 Feb 2022 18:00:00 -0000 00:26:08 http://www.morningcommutepodcast.com/solidtumors1 Our faculty discuss the exciting developments in antibody-drug conjugate therapy for human epidermal growth factor receptor 2-positive breast cancer.

Visit www.morningcommutepodcast.com/solidtumors1 to view the activity and CME/CE information, download the transcript, and complete the post-test and evaluation to earn CME/CE credit

]]> Oncology Morning Commute: Antibody Drug Conjugates and HER2-Positive Breast Cancer no 6 1 S5:E6 – Multiple Myeloma Morning Commute: Tolerable and Sustainable Treatments for Multiple Myeloma https://pinecast.com/guid/d7b9dcc8-5533-43a9-871b-e8eaa5c3e362 Wed, 31 Mar 2021 22:45:00 -0000 00:15:15 http://morningcommutepodcast.com/multiplemyeloma6 Visit http://morningcommutepodcast.com/multiplemyeloma6 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Ravi Vij and Dr. Thomas Martin will discuss the many treatments for multiple myeloma with a look at how to use them to manage the disease and derive maximum benefit for this patient population. What are some common side effects and how are they managed?

]]> Multiple Myeloma Morning Commute: Tolerable and Sustainable Treatments for Multiple Myeloma no 5 6 S5:E5 – Multiple Myeloma Morning Commute: New and Emerging Multiple Myeloma Treatments– Giving the Snowball a Chance https://pinecast.com/guid/3a9306c4-b133-4ce7-b24f-257a6a5a3021 Wed, 31 Mar 2021 22:39:00 -0000 00:17:44 http://morningcommutepodcast.com/multiplemyeloma5 Visit http://morningcommutepodcast.com/multiplemyeloma5 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Ravi Vij and Dr. Thomas Martin will discuss some of the new and emerging therapies for the treatment of triple-class refractory multiple myeloma in a rapid-fire discussion that you won’t want to miss.

]]> Multiple Myeloma Morning Commute: New and Emerging Multiple Myeloma Treatments– Giving the Snowball a Chance no 5 5 S5:E4 – Multiple Myeloma Morning Commute: BCMA as a Therapeutic Target for Multiple Myeloma https://pinecast.com/guid/cd132061-b69e-4fac-925e-c26c02c5c7b7 Wed, 31 Mar 2021 22:00:00 -0000 00:17:44 http://morningcommutepodcast.com/multiplemyeloma4 Visit http://morningcommutepodcast.com/multiplemyeloma4 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. Ravi Vij and Dr. Thomas Martin discuss the growing excitement around chimeric antigen receptor T-cell, or CAR-T, therapies that target B-cell maturation antigen, or BCMA, for the treatment of multiple myeloma.

]]> Multiple Myeloma Morning Commute: BCMA as a Therapeutic Target for Multiple Myeloma no 5 4 S5:E3 – Multiple Myeloma Morning Commute: Another Tool in the RRMM Toolbox https://pinecast.com/guid/cc5f10d6-ad8c-4973-ab10-895dceb37cc1 Wed, 31 Mar 2021 21:30:00 -0000 00:14:20 http://morningcommutepodcast.com/multiplemyeloma3 Visit http://morningcommutepodcast.com/multiplemyeloma3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, Dr. Ravi Vij and Dr. Thomas Martin take a look at one of the newest drugs for the treatment of multiple myeloma, the just-approved melflufen. They discuss the clinical data that led to its approval and the patients for whom it may show benefit.

]]> Multiple Myeloma Morning Commute: Another Tool in the RRMM Toolbox no 5 3 S5:E2 – Multiple Myeloma Morning Commute: Can We Do Better in Relapsed/Refractory Disease? https://pinecast.com/guid/20504512-6ee0-4c6e-86e0-4e53b9b5a253 Wed, 31 Mar 2021 21:00:00 -0000 00:14:27 http://morningcommutepodcast.com/multiplemyeloma2 Visit http://morningcommutepodcast.com/multiplemyeloma2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Ravi Vij, and Dr. Thomas Martin take a look at selinexor, isatuximab, and belantamab and how these are fitting in with current clinical practice.

]]> Multiple Myeloma Morning Commute: Can We Do Better in Relapsed/Refractory Disease? no 5 2 S5:E1 – Multiple Myeloma Morning Commute: Standard Care for the Newly Relapsed Patient https://pinecast.com/guid/63db9d59-9b1c-4960-a657-52e060e5de15 Wed, 31 Mar 2021 20:45:00 -0000 00:14:54 http://morningcommutepodcast.com/multiplemyeloma1 Visit http://morningcommutepodcast.com/MultipleMyeloma1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. Rvi Vij and Dr. Thomas Martin will discuss treatment of multiple myeloma in patients who have relapsed. Most of these patients are on maintenance therapy, so how do you select the right regimen for them? The good news is that there are many from which to choose.

]]> Multiple Myeloma Morning Commute: Standard Care for the Newly Relapsed Patient no 5 1 S3:E3 – Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon? https://pinecast.com/guid/bf18ee2f-049f-41c2-bf9a-cae9c8d1af56 Thu, 11 Feb 2021 19:20:00 -0000 00:30:05 http://www.MorningCommutePodcast.com/NSCLC3 Visit MorningCommutePodcast.com/NSCLC3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss New therapies in the pipeline as well as immunotherapy combinations.  At the time this podcast was recorded, cemiplimab was pending approval.

]]> Non-Small Cell Lung Cancer Morning Commute: What’s on the Horizon? no 3 3 S3:E2 – Non-Small Cell Lung Cancer Morning Commute: When and Why to Skip the Chemotherapy https://pinecast.com/guid/1bafc601-5ef8-40a4-9cb2-e9c69f80d176 Thu, 11 Feb 2021 19:10:00 -0000 00:24:45 http://www.MorningCommutePodcast.com/NSCLC2 Visit MorningCommutePodcast.com/NSCLC2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts discuss PD-L1 levels, do they matter, as well as choosing the best candidates for Immune checkpoint inhibitor therapy not combined with chemotherapy, and they will also touch on recognizing adverse events.

]]> Non-Small Cell Lung Cancer Morning Commute: When and Why to Skip the Chemotherapy no 3 2 S3:E1 – Non-Small Cell Lung Cancer Morning Commute: The Newly Diagnosed Patient https://pinecast.com/guid/3066e596-095f-49c2-b16e-054a59ff980d Thu, 11 Feb 2021 19:00:00 -0000 00:26:13 http://www.MorningCommutePodcast.com/NSCLC1 Visit MorningCommutePodcast.com/NSCLC1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode our experts discuss the current standards of care regarding patient work-up, diagnosis, as well as PD-L1 expression and emerging immunotherapy biomarkers in treatment selection for non-small cell lung cancer.

]]> Non-Small Cell Lung Cancer Morning Commute: The Newly Diagnosed Patient no 3 1 S2:E2 – Oncology Journal Club: Special Considerations in Chronic Lymphocytic Leukemia and Covid-19 https://pinecast.com/guid/19363bcd-a189-45ce-bc91-0f77c23d445c Mon, 25 Jan 2021 18:53:40 -0000 http://journalclubpodcasts.com/cll Visit http://journalclubpodcasts.com/cll to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this Journal Club Podcast our expert faculty look at treatment of CLL patients with Covid-19, specifically BTK-inhibitors and monoclonal anti-CD20 antibodies.

]]> Oncology Journal Club: Special Considerations in Chronic Lymphocytic Leukemia and Covid-19 no 2 2 S2:E1 – Oncology Journal Club: Special Considerations in Clinical Oncology and Covid-19 https://pinecast.com/guid/c7b7abc2-178b-4926-b6f3-f7f63bc978fb Wed, 04 Nov 2020 22:01:08 -0000 00:30:27 http://journalclubpodcasts.com/clinicaloncology Visit journalclubpodcasts.com/clinicaloncology to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts discuss the findings of a study published in Lancet Oncology that suggests Covid-19 appears to have a different trajectory for patients depending on the type of cancer that they have. Patients with hematologic cancers–leukemia, lymphoma, myeloma–developed more severe Covid-19 compared with those with solid tumors.

]]> Oncology Journal Club: Special Considerations in Clinical Oncology and Covid-19 no 2 1 S1:E3 – Endometrial Cancers Morning Commute: Matching the Right Treatment to the Right Patient https://pinecast.com/guid/192d423c-a1b6-4ffe-868f-9b47271e13bc Fri, 31 Jul 2020 17:33:26 -0000 00:28:25 Visit morningcommutepodcast.com/endometrial1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts on endometrial cancer discuss immune checkpoint inhibitors, including therapeutic rationale and their safety and efficacy as single agents and in combination therapies.

]]> Endometrial Cancers Morning Commute: Matching the Right Treatment to the Right Patient no 1 3 S1:E2 – Endometrial Cancers Morning Commute: Immunotherapy - A New Player in Endometrial Cancer Treatment https://pinecast.com/guid/e3aa87eb-caf1-4dd8-86f7-c9bbf0ef8d78 Fri, 31 Jul 2020 08:00:00 -0000 00:21:45 Visit morningcommutepodcast.com/endometrial2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts on endometrial cancer discuss patient selection, toxicities, toxicity management, and how new therapies are entering into the clinical domain with increasing frequency.

]]> Endometrial Cancers Morning Commute: Immunotherapy - A New Player in Endometrial Cancer Treatment no 1 2